CPSE:NOVO BPharmaceuticals
Novo Nordisk (CPSE:NOVO B) Could Be 16% Overvalued On Medicare Wegovy Coverage
Novo Nordisk (CPSE:NOVO B) is back in focus after Medicare’s new GLP-1 Bridge program started covering its weight loss drug Wegovy, opening a lower cost access route for millions of older adults.
See our latest analysis for Novo Nordisk.
Against this backdrop of expanded Medicare access for Wegovy, Novo Nordisk’s share price has climbed strongly in the short term, with a 30 day share price return of 19.57% and a 90 day gain of 40.14%. However, the 1 year total shareholder return is down...